Biotech · Private company
Ophthotech Corporation
Track this companyFree. Adds Ophthotech Corporation to your Dealase workspace and tells you when its record changes.
Clinical trials120 recruiting or active
Pipeline programs17From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline17
- bevacizumab or afliberceptPhase 3 · Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- E10030Phase 3 · Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- E10030 sham injectionPhase 3 · Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- E10030 sham intravitreal injectionPhase 3 · Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- ranibizumabPhase 3 · Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- afliberceptPhase 2 · Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- Avacincaptad PegolPhase 2 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- Avacincaptad PegolPhase 2 · Idiopathic Polypoidal Choroidal VasculopathyClinicalTrials.gov · fetched Nov 12, 2026
- bevacizumabPhase 2 · Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- E10030 plus LucentisPhase 2 · Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- EyleaPhase 2 · Idiopathic Polypoidal Choroidal VasculopathyClinicalTrials.gov · fetched Nov 12, 2026
- Fovista®Phase 2 · Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- Fovista® (anti-PDGF BB) plus anti-VEGFPhase 2 · Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- LucentisPhase 2 · Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- LucentisPhase 2 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- ZimuraPhase 2 · Idiopathic Polypoidal Choroidal VasculopathyClinicalTrials.gov · fetched Nov 12, 2026
- Avacincaptad PegolPhase 1 · Dry Age-Related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials12
- ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)PHASE2 · WITHDRAWN · started Nov 1, 2018ClinicalTrials.gov NCT03374670 · fetched Nov 12, 2026
- ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)PHASE2 · COMPLETED · started Oct 11, 2017ClinicalTrials.gov NCT03362190 · fetched Nov 12, 2026
- A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)PHASE2 · TERMINATED · started Apr 26, 2016ClinicalTrials.gov NCT02387957 · fetched Nov 12, 2026
- A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)PHASE2 · COMPLETED · started Mar 12, 2015ClinicalTrials.gov NCT02397954 · fetched Nov 12, 2026
- Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMDPHASE2 · TERMINATED · started Jul 1, 2014ClinicalTrials.gov NCT02214628 · fetched Nov 12, 2026
- A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® MonotherapyPHASE3 · TERMINATED · started May 1, 2014ClinicalTrials.gov NCT01940887 · fetched Nov 12, 2026
- A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® MonotherapyPHASE3 · TERMINATED · started Aug 1, 2013ClinicalTrials.gov NCT01940900 · fetched Nov 12, 2026
- A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® MonotherapyPHASE3 · TERMINATED · started Aug 1, 2013ClinicalTrials.gov NCT01944839 · fetched Nov 12, 2026
- A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular DegenerationPHASE2 · COMPLETED · started Mar 1, 2010ClinicalTrials.gov NCT01089517 · fetched Nov 12, 2026
- A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular DegenerationPHASE1 · COMPLETED · started Jul 16, 2009ClinicalTrials.gov NCT00950638 · fetched Nov 12, 2026
- ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular DegenerationPHASE1 · COMPLETED · started Oct 16, 2008ClinicalTrials.gov NCT00709527 · fetched Nov 12, 2026
- A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular DegenerationPHASE1 · COMPLETED · started Dec 1, 2007ClinicalTrials.gov NCT00569140 · fetched Nov 12, 2026